IPBronch.com | Interventional Pulmonology

Thorax Jul 15, 2026

Enhanced diagnosis of tuberculous pleurisy using a multiplex droplet digital PCR assay targeting circulating mycobacterial DNA.

Study Takeaway

This novel diagnostic tool could significantly improve the yield of thoracentesis in patients with suspected tuberculous pleural effusions.

Zhang S; Xu Y; Huang M; Pan Y; Shangguan J; Peng R

IP Score: 8/10 View Analysis →

Thorax Jul 15, 2026

Optimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies.

Study Takeaway

Understanding the evolving landscape of mesothelioma treatment is essential for interventional pulmonologists managing pleural biopsies and indwelling pleural catheters.

Blanquart C; Scherpereel A

IP Score: 6/10 View Analysis →

Thorax Jul 15, 2026

Rethinking pleural tuberculosis through the lens of cell-free DNA.

Study Takeaway

Potential for molecular diagnostics to augment traditional pleural fluid analysis in undiagnosed exudative effusions.

Bedawi EO; Rahman NM

IP Score: 6/10 View Analysis →

BMC pulmonary medicine Jul 6, 2026

A novel percutaneous aspiration sclerotherapy for staged volume reduction of giant single bulla in the treatment of COPD combined with pulmonary bullae.

Study Takeaway

Introduces a minimally invasive procedural alternative for bullous disease management that may be relevant to IP practice.

Deng W; Li C; Jiang Y; Hu X; Jiang Y; Jiang G

IP Score: 8/10 View Analysis →

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Jul 1, 2026

The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and Programmed Death-Ligand 1 Expression on Overall Survival in a Select Cohort From the International Association for the Study of Lung Cancer Ninth Edition Staging Database.

Study Takeaway

Relevant for IP clinicians involved in the diagnostic workup and tissue acquisition for mesothelioma staging.

Yang SR; Tjota MY; Goren E; Giroux DJ; Galateau-Salle F; Husain AN

IP Score: 6/10 View Analysis →

Respiratory medicine Jun 30, 2026

Lung ultrasound in interstitial lung disease: from bedside screening to prognostic integration and AI-assisted standardization.

Study Takeaway

Lung ultrasound proficiency is increasingly relevant for interventional pulmonologists managing pleural and parenchymal disease at the bedside.

Yang J; Lin Y; Bai J; Zhu Z; Lian X

IP Score: 6/10 View Analysis →

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Jun 20, 2026

Amivantamab induces immune-mediated cytotoxicity in mesothelioma via EGFR and MET engagement.

Study Takeaway

Provides a potential future systemic therapeutic target for mesothelioma, which may influence the role of pleural biopsies and tissue acquisition in clinical trials.

Suzuki S; Parikh K; Tolosa E; Wu KL; Mopuri R; Ayers-Ringler J

IP Score: 6/10 View Analysis →

Respiratory research Jun 17, 2026

The LTI-01-2001 phase 2a trial of intrapleural LTI-01 in patients with infected, non-draining pleural effusions.

Study Takeaway

LTI-01 represents a significant pharmacological advancement in the management of complicated parapneumonic effusions and empyema, potentially reducing the need for surgical intervention.

Lamb CR; Akulian J; Musani A; Shojaee S; Chen A; Kurman J

IP Score: 9/10 View Analysis →

Respiratory research Jun 12, 2026

Identifying molecular signatures of parapneumonic effusion reveals HMGB2 as the disease progression biomarker.

Study Takeaway

Provides molecular insight into pleural space infection, which may eventually inform decision-making for pleural drainage or fibrinolytic therapy.

Wu KA; Chen M; Wu KL; Lai CH; Chang IY; Jan FW

IP Score: 6/10 View Analysis →

Respiratory medicine May 28, 2026

High ASA-PS as an Independent Predictor of Refractoriness and Poor Prognosis in Secondary Spontaneous Pneumothorax.

Study Takeaway

Pre-procedural risk stratification using ASA-PS may help identify patients who will require early intervention or advanced pleural management for persistent air leaks.

Nonomura R; Niikawa H; Yabe R; Nagata H; Ueda K; Oshima Y

IP Score: 8/10 View Analysis →

The European respiratory journal May 14, 2026

The Third Pleural Effusion and Symptom Evaluation (PLEASE-3) Study: Bendopnoea in patients with pleural effusion

Study Takeaway

Bendopnoea may serve as a useful clinical marker for assessing the symptomatic burden of pleural effusions in the IP clinic.

Iacopetta BM; Roy B; Budgeon CA; Donaghy M; Ing M; Charlesworth C

IP Score: 7/10 View Analysis →

Thorax May 8, 2026

National mesothelioma networks: platforms for better care and research opportunities.

Study Takeaway

Reinforces the need for IP involvement in structured, multidisciplinary mesothelioma care pathways.

Bibby AC

IP Score: 6/10 View Analysis →

Literature Archives